Immunofluorescence analysis show that treatment with cisplatin enhanced the expression of both CD44 and Oct4 in bladder cancer cells (Figure 3A), Notably, CD44 was colocalized with Oct4, suggesting concurrent upregulation of CD44 and Oct4 during cisplatin treatment. Here, POU5F1 is linked to urinary bladder cancer.